Industry

DUBLIN–(BUSINESS WIRE)–The “Pregnancy Detection Kits Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering. The Pregnancy Detection Kits Market was valued at USD 1.84 Billion in 2024, and is expected to reach USD 2.58 Billion by 2030, rising at a CAGR of 5.80%. The market is … [Read more…]

VANCOUVER, British Columbia–(BUSINESS WIRE)–WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general meeting held June 30, 2025 (the “Meeting”), all of the … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well … [Read more…]

BRANFORD, Conn.–(BUSINESS WIRE)–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 29,940,119 shares of common stock (and common stock equivalents) at a purchase … [Read more…]

Breast cancer patients face devastating consequences for access to critical breast cancer care   DALLAS–(BUSINESS WIRE)–Susan G. Komen®, the world’s leading nonprofit breast cancer organization, is deeply troubled by passage of the One Big Beautiful Bill Act which implements damaging reforms to federal health insurance programs. The Congressional Budget Office estimates these changes, combined with … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031” report has been added to ResearchAndMarkets.com’s offering. Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions: Gamma Delta T Cell Therapies In Clinical Trials: > 25 Therapies Highest Phase … [Read more…]

New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas–(BUSINESS WIRE)–$IPA #AI–ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered … [Read more…]

WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 … [Read more…]

BAAR, Switzerland & OSAKA, Japan & TOKYO–(BUSINESS WIRE)–Stallergenes Greer, Shionogi & Co., Ltd. (“Shionogi”) and CEOLIA Pharma Co. Ltd (“CEOLIA”) today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. After ending the license … [Read more…]

Reflects the Company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla.–(BUSINESS WIRE)–$DYAI #BioSolutions–Dyadic International, Inc. (“Dyadic”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and … [Read more…]